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McGill University, Montreal, Canada; and ††Universite´ Bordeaux 1, Institut LYRIC, Bordeaux, FranceABSTRACT Atrial fibrillation (AF) is the most common type of clinical arrhythmia. Currently available anti-AF drugs are limited
by only moderate efficacy and an unfavorable safety profile. Thus, there is a recognized need for improved antiarrhythmic agents
with actions that are selective for the fibrillating atrium. State-dependent Naþ-channel blockade potentially allows for the devel-
opment of drugs with maximal actions on fibrillating atrial tissue andminimal actions on ventricular tissue at resting heart rates. In
this study, we applied a mathematical model of state-dependent Naþ-channel blocking (class I antiarrhythmic drug) action, along
with mathematical models of canine atrial and ventricular cardiomyocyte action potentials, AF, and ventricular proarrhythmia, to
determine the relationship between their pharmacodynamic properties and atrial-selectivity, AF-selectivity (atrial Naþ-channel
block at AF rates versus ventricular block at resting rates), AF-termination effectiveness, and ventricular proarrhythmic proper-
ties. We found that drugs that target inactivated channels are AF-selective, whereas drugs that target activated channels are not.
The most AF-selective drugs were associated with minimal ventricular proarrhythmic potential and terminated AF in 33% of
simulations; slightly fewer AF-selective agents achieved termination rates of 100% with low ventricular proarrhythmic potential.
Our results define properties associated with AF-selective actions of class-I antiarrhythmic drugs and support the idea that it may
be possible to develop class I antiarrhythmic agents with optimized pharmacodynamic properties for AF treatment.INTRODUCTIONAtrial fibrillation (AF) is the most common type of sus-
tained cardiac arrhythmia (1). AF is associated with reduced
quality of life and increased morbidity and mortality (2).
Antiarrhythmic drugs have long been used to treat AF (1),
but the use of antiarrhythmic agents has markedly decreased
because of limited drug efficacy and the risk of serious
complications, particularly ventricular proarrhythmia
(2–5). In animal and mathematical models, Naþ-channel
blockers terminate AF by increasing the excitable gap and
promoting the extinction of arrhythmia-maintaining rotors
(6–8); however, they can also increase arrhythmic mortality
(9). Recent experimental data suggest that Naþ-channel
blockers can be atrial-selective (10,11), causing minimal
ventricular effects. Thus, there is a strong interest in the
development of AF-selective antiarrhythmic drugs with
optimized efficacy and safety profiles (3).
We hypothesized that we could maximize the atrial
antiarrhythmic properties of Naþ-channel blockers and
minimize their proarrhythmic potential by identifying
pharmacodynamic parameters optimized for selective
actions on atrial tissue during AF. In this work, we address
the question of how the Naþ-channel blocking kinetics
influences atrial selectivity and the rate dependence ofSubmitted September 14, 2011, and accepted for publication January 20,
2012.
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0006-3495/12/03/0951/10 $2.00block, anti-AF efficacy, and ventricular proarrhythmic
potential.MATERIALS AND METHODS
Guarded-receptor model
To simulate state-dependent sodium current (INa) block, we used the
guarded-receptor model, in which a voltage-sensitive channel gate restricts
drug access to and from a constant-affinity channel-binding site (12). We
assumed that the Naþ-channel blocker could bind to the Naþ-channel
during either the activated (A) or inactivated (I) state. The drug’s binding
and unbinding kinetics are described by first-order transitions, with kA
and kI being binding rate constants from activated and inactivated states,
respectively, and lA and lI corresponding to the unbinding rate constants
(Fig. 1). We computed the fraction of channels blocked in activated or in-
activated states (BA and BI, respectively) using the following equations:
INa ¼ gNað1 BA  BIÞm3hjðV  ENaÞ (1)
dBA 3 zVF=RT
dt
¼ kA½Dm hjð1 BA  BIÞ  lABA e (2)
dBI zVF=RT
dt
¼ kI½Dð1 hÞð1 BA  BIÞ  lIBI e ; (3)
where gNa is the Na
þ conductance; BA and BI are the fractional activated-
and inactivated-state blocks, respectively; m is the activation variable;
h and j are inactivation variables; V is the membrane potential; ENa is the
Naþ equilibrium potential; z is the drug charge; F is Faraday’s constant;
R is the universal gas constant; T is temperature; and [D] is the drug concen-
tration (12). We assumed that z ¼ 0 (uncharged drug) for the main analysis,
but also considered a positively charged molecule (z ¼ þ1) in single-celldoi: 10.1016/j.bpj.2012.01.032
FIGURE 1 Schematic representation of the
guarded-receptor model of Naþ-channel-blocking
action. Transitions between the closed, activated
(A), and inactivated (I) states are governed by
Hodgkin-Huxley equations with rate constants ax
and bx. Transitions between unblocked and
blocked states are governed by binding-rate
constants, kA and kI, and unbinding-rate constants,
lA and lI.
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at a drug concentration of 60 mM.Single-cell simulations
The Ramirez-Nattel-Courtemanche (RNC) ionic model of atrial cardio-
myocytes (13) and the Hund-Rudy (HRd) ionic model of ventricular cardi-
omyocytes (14) were implemented.
The total ionic current for the RNC model (Iion,RNC) is
Iion;RNC ¼ INa þ IK l þ Ito þ IKur;d þ IKr þ IKs
þ ICa;L þ IClCa þ IK;ACh þ IpCa þ INaCa
þ INaK þ Ib;Na þ Ib;Ca þ Ib;Cl;
where IK1, Ito, IKur,d, IKr, IKs, and IK,ACh are the inward rectifier, transient
outward, ultrarapid delayed rectifier, rapid and slow delayed rectifiers,and acetylcholine (ACh)-activated Kþ currents respectively; ICa,L is the
L-type Ca2þ current; IClCa is the Ca
2þ-activated Cl current; IpCa is
the Ca2þ pump current; INaCa is the Na
þ/Ca2þ exchange current; INaK is
the Naþ/Kþ pump current; and Ib,Na, Ib,Ca, and Ib,Cl are the background
Naþ, Ca2þ, and Cl currents, respectively (15).
The total ionic current for the HRd model (Iion,HRd) is
Iion;HRd ¼ ICa;t þ INa;t þ IK;t þ ICl;t
withICa;t ¼ ICa;L þ Ib;Ca þ IpCa  2INaCa
INa;t ¼ INa þ 3INaK þ ICaNa þ 3INaCa þ INa;LIK;t ¼ IKs þ IKr þ IK1 þ ICaK þ Ito1 þ Ito2  2INaKICl;t ¼ Ito2 þ Ib;ClBiophysical Journal 102(5) 951–960where ICaNa is the Na
þ current though the L-type Ca2þ channel, INa,L is the
slowly inactivating late Naþ current, ICaK is the Ca
2þ-dependent Kþ
current, Ito1 is the 4AP-sensitive transient outward K
þ current, and Ito2 is
the Ca2þ-dependent transient outward Cl current (with other terms as
defined above) (14).
RNC and HRd cardiomyocytes at 37C were stimulated at 1 Hz (sinus
rhythm frequency) and 6 Hz (AF equivalent frequency) for 3 min for
each set of rate constants by numerical integration with the MATLAB
ODE23s ordinary differential equation solver (The MathWorks, Natick,
MA). The stimuli were 30 pA/pF 2-ms square pulses. A Naþ-channel
blocker was added after 1 min and the drug effect was quantified based
on a reduction in peak INa (Bss ¼ INa,CTL  INa,drug/INa,CTL). We changed
the rate constants one at a time to study the effect of each parameter. For
a fixed set of kA and kI, lA and lI were varied from 10
7 to 10 ms1 in
100.5 ms1 intervals, generating 225 simulations for each kA-kI combina-
tion. The binding rate constants were then varied over kA-kI parameter space
(kA ¼ {100, 101, 102, 103, 104, 105} ms1mol1, and kI ¼ {1, 20, 100, 500,
2500} ms1mol1), and for each kA-kI combination, lA and lI were varied,
generating 4500 simulations each for the atrial cell paced at 1 Hz, the atrial
cell paced at 6 Hz, and the ventricular cell paced at 1 Hz (for a total of
13,500 single-cell simulations). Rate-constant combinations with
Bss < 50% were excluded from optimization because at least 50% Na
þ-
channel blockade is required for AF termination (8).
We defined rate-selectivity as the ratio of Bss in an atrial cell paced at
6 Hz and an atrial cell paced at 1 Hz (Bss atrial 6 Hz / Bss atrial 1 Hz).
Atrial-selectivity was defined as the ratio of Bss in an atrial cell paced at
1 Hz and a ventricular cell paced at 1 Hz (Bss atrial 1 Hz / Bss ventricular
1 Hz). We defined overall AF-selectivity as the product of rate-selectivity
and atrial-selectivity (Bss atrial 6 Hz / Bss ventricular 1 Hz).
We repeated the analysis for four clinically used Naþ-channel blockers
(lidocaine, procainamide, ranolazine, and flecainide) with rate constants
from the literature over a clinically relevant concentration range, as
follows: lidocaine: kA ¼ 5173 ms1mol1, kI ¼ 4998 ms1mol1,
lA ¼ 0.0128 ms1, and lI ¼ 0.0384 ms1 (16); procainamide: kA ¼
260 ms1mol1, kI ¼ 0.0 ms1mol1, lA ¼ 0.000058 ms1, lI ¼
0.0 ms1 (17); ranolazine: kA ¼ 2970 ms1mol1, kI ¼ 0.0 ms1mol1,
lA¼ 0.0053ms1, lI¼ 0.0ms1 (11); and flecainide: kA¼ 5830ms1mol1,
kI ¼ 0.0 ms1mol1, lA ¼ 0.31 ms1, lI ¼ 0.0 ms1 (18).
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We explored the vulnerable period (VP) and proarrhythmic index (PI) on
a one-dimensional (1D) cable of ventricular myocytes as indices of proar-
rhythmic potential (19). We constructed a 10-cm cable of HRd ventricular
myocytes by linking excitable segments with a 250 U cm axial resistivity,
100 mm length, and 11 mm radius. We stimulated the cable at 1 Hz at one
end to achieve pseudo-steady-state Naþ-channel blockade after Naþ-
channel blocker addition.
To measure VP, we applied a conditioning stimulus (S1) at one end and
a 3-cm test stimulus (S2) 3 cm from one end. The VP was the range of
S1-S2 delays that caused unidirectional propagation (20). We defined the
PI as VP/(CL  RP), where CL is the pacing cycle length and RP is the
refractory period (21).Two-dimensional simulations
Two-dimensional (2D) simulations were performed on a 6.5 7.0 cm sheet
of RNC atrial cells. The tissue contained cardiomyocyte cables (radius
5 mm, resistivity 75 U cm coupled by resistors (300 kU), length 100 mm,
inserted in a brick-wall manner). Fiber resistivity and interfiber resistance
values were chosen to match experimental results (15,22). AF was started
by a cross-shock protocol, with S1 applied at one edge and S2 applied on
a square area. The ACh effect simulated vagal tone, following a sinusoidal
distribution with peak [ACh] of 15.0 nM, as previously described (8,15).
We refer to the AF that continued for the full simulation (10 s) as sustained
AF. Naþ-channel blockers were added at six time points (tDRUG ¼ {948,
974, 1000, 1050, 1065, 1075} ms) for every optimal rate constant combina-
tion defined by single-cell optimization, generating 120 simulations (six
different tDRUG values for 30 kA-kI combinations). Drug efficacy was ex-
pressed as the percentage of successful AF terminations for each rate-
constant combination.AF-selectivity optimization
We optimized AF-selectivity, the product of rate- and atrial-selectivity,
using the single-cell analysis. We identified the lA-lI with maximalFIGURE 2 (A–C) Reduction in INa (Bss) for an atrial myocyte paced at 6 Hz (A
lA and lI for kA¼ 104 and kI¼ 20 ms1 mol1. (D and E) Rate- and atrial-selecti
Color scales are at the right of each panel.AF-selectivity (lA,max, lI,max) for each kA-kI combination, yielding 30 (kA,
kI, lA,max, lI,max) combinations. We then used this {kA, kI, lA,max, lI,max}
set to study AF termination efficacy for each of the 30 (kA, kI, lA,max, lI,max)
combinations. The optimized set of binding parameters {kA, kI, lA,max,
lI,max} generated little variation in the PIs because the rate-constant combi-
nations had been selected to minimize ventricular actions. We therefore
repeated the proarrhythmia analysis by fixing lA ¼ 103 ms1 and lI ¼
102 ms1 (optimally AF-selective values in single-cell analysis), and
systematically varying kA and kI.RESULTS
Selectivity and binding rate constants
We first computed the drug-induced reduction in peak INa
(Bss) as a function of the unbinding rate constants, lA and
lI, for a fixed set of binding rate constants, kA ¼ 104
ms1mol1 and kI ¼ 20 ms1 mol1 (Fig. 2, A–C). Bss
was frequency-dependent and reached almost 100% at low
lA and/or lI. The lA-lI parameter space for high Bss was
largest for the atrial myocyte at 6 Hz, producing a region
with Bss that was clearly greater in atrial cells at 6 Hz
than at 1 Hz. Fig. 2 D shows the rate-selectivity, which
was greater than unity over a small region of lA-lI space.
The maximum values for atrial-selectivity were consider-
ably smaller than those for rate-selectivity (Fig. 2 E), and
in no case exceeded 1.5. AF-selectivity (Fig. 2 F) showed
a discrete area of large values, with a maximum of 5.8 at
lA,max and lI,max of 10
3.5 ms1 and 102 ms1, respectively.
After examining the role of unbinding (lA and lI), we as-
sessed the dependency of block on binding (kA and kI). We
first defined lA,max and lI,max as the values of lA and lI that
maximize the AF-selectivity for a fixed kA and kI by varying) and 1 Hz (B), and a ventricular myocyte paced at 1 Hz (C) as a function of
vities. (F) AF-selectivity. Maximum AF-selectivity is shown by the asterisk.
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7 to 100 ms1 in 100.5 ms1
intervals. We defined AF-selectivitymax as the AF-selectivity
index at (lA,max, lI,max) for each kA and kI, varying kA and kI
independently (kA ¼ {100, 101, 102, 103, 104, 105} ms1
mol1, kI ¼ {1, 20, 100, 500, 2500} ms1 mol1) to
compute AF-selectivitymax over kA-kI parameter space.
Fig. 3, A–C, shows the resulting rate-selectivity, atrial-
selectivity, and AF-selectivitymax. In general, rate-
selectivity and AF-selectivity increased with increasing
inactivated-state affinity and decreased with activated-state
affinity. However, AF-selectivity fell off with increases in
kI beyond a maximum at 500 ms
1mol1. The rate constants
with the greatest AF-selectivity (kA ¼ 1 ms1 mol1,
kI¼ 500 ms1 mol1, lA¼ lI¼ 102 ms1) had a rate-selec-
tivity of 12.8, atrial-selectivity of 1.93, and AF-
selectivitymax of 24.6. Fig. 3, D and E, show the fraction
of Naþ-channels blocked in activated (BA) and inactivated
(BI) states for various kinetic constants, at the onset of the
pseudo-steady-state action potential. Fig. 3 F shows BA
and BI as a function of AF-selectivitymax. High AF-
selectivitymax values were associated with low BA and
high BI, confirming preferential targeting of the inactivated
state. The lA and lI values corresponding to the data in Fig. 3,
A–E, are shown in Fig. 3, G and H, with lA showing more
variation than lI for different kA-kI combinations. For
comparison, results for four clinical Naþ-channel blockers
are shown in Table S1 in the Supporting Material.
Rate-selectivities were highest for low-dose lidocaine and
procainamide, with flecainide and ranolazine being the least
rate-selective. Atrial-selectivities were relatively low except
for ranolazine, which had an atrial-selectivity of ~3
compared with 1.1–1.9 for the other compounds. AF-selec-
tivities ranged from 7.8 to 15.6 for lidocaine, 7.2 to 9.5 for
procainamide, 1.0 to 1.1 for flecainide, and 5.2 to 6.6Biophysical Journal 102(5) 951–960for ranolazine, and dropped off at higher concentrations
for all drugs.
Finally, because ventricular proarrhythmia can arise at
rates higher than normal sinus rhythm, we repeated the
simulations and computed atrial-selectivity as the ratio of
drug-induced reduction in INa,max of an atrial cell at 6 Hz
versus a ventricular cell at 2.5 Hz (Fig. S1). Optimal AF-
selectivity continued to occur with inactivated-state
blockers, albeit with a shift in optimal rate constants and
a decrease in maximal AF-selectivity.
Fig. 4 shows atrial and ventricular action potentials
(A–C), Naþ-current (D–F) and fractional block (G–I) in
activated (BA) and inactivated (BI) states pre- and postdrug
for the optimally AF-selective blocker (kA ¼ 10 ms1
mol1, kI ¼ 500 ms1 mol1, lA ¼ lI ¼ 102 ms1). Effects
were largest for the atrial cardiomyocyte at 6 Hz (Fig. 4, A
and D). At 6 Hz, activated-state block was almost zero,
whereas inactivated-state fractional block varied between
60% and 75% over the cycle (Fig. 4 G). At slower frequen-
cies, inactivated-state block declined to zero over each cycle
(Fig. 4, H and I).
We expanded our analysis (Fig. S2) by repeating the
single-cell optimization with a positively charged molecule
(z ¼ þ1) instead of a neutral molecule (z ¼ 0). Optimal
AF-selectivity continued to be associated with higher kI
and lower kA values, but rate-selectivity and AF-selectivity
were higher for the charged molecules, with maximal
AF-selectivity ¼ 89.1 vs. 24.6 for the uncharged molecule.Ventricular proarrhythmia
We initially analyzed the proarrhythmic potential with the
optimized rate constants, but found very little variation in
CV and VP (Fig. S3). Because lA and lI had been selectedFIGURE 3 (A–C) Rate-selectivity, atrial-selec-
tivity, and AF-selectivitymax as a function of the
binding-rate constants kA and kI. (D and E) Frac-
tional block for activated (BA) and inactivated
(BI) states. (F) Fractional block (BA and BI) versus
AF-selectivitymax, with schematic curves (dashed
lines). (G and H) Unbinding-rate constants (lA,max
and lI,max) corresponding to kA-kI parameter space.
An area of large AF-selectivity (at kA ¼
101103 ms1 mol1 and kI ¼ 100 ms1 mol1)
with low proarrhythmic risk and high AF-termina-
tion rates (see Figs. 5 and 6) is shown in black
boxes.
FIGURE 4 Action potentials, Naþ current (INa),
and fractional block for the optimally AF-selective
Naþ-channel blocker (kA ¼ 10 ms1 mol1, kI ¼
500 ms1 mol1, lA ¼ lI ¼ 102 ms1). (A–C)
Effects on an atrial cell paced at 6 Hz, an atrial
cell paced at 1 Hz, and a ventricular cell paced at
1 Hz. In all panels, the vertical red line corresponds
to tDRUG, the time at which the drug was added.
(D–F) Corresponding values of INa. (G–I) Frac-
tional block in the activated (BA, green) and inac-
tivated (BI, lavender) states. Panels H and I
illustrate the temporal dynamics of block: BI rises
sharply just after the action potential upstroke, cor-
responding to the onset of inactivation. It then rea-
ches a plateau and starts to decrease at the end of
the action potential, when the Naþ channels
recover from inactivation. BA is negligible. The
atrial cell paced at 6 Hz had a much larger BI
than atrial and ventricular cells paced at 1 Hz,
because of the reduced unbinding time between
action potentials.
AF-Selective Sodium Channel Blockade 955to maximize AF-selectivity, ventricular effects were mini-
mized. We therefore repeated the analysis, fixing the
unbinding rate constants (lA, lI) at optimally AF-selective
values (lA ¼ 103 ms1 and lI ¼ 102 ms1), varied kA
and kI, and recomputed CV, VP, and PI. For kA from 10
0
to 104 ms1mol1, CV was preserved, and VP and PI
were minimal (Fig. 5, A–C). There was a sharp drop in
CV (from ~55 to 39 cm/s) and increase in PI and VP
(maximum increase ¼ 55% and 32% respectively) atFIGURE 5 (A) Conduction velocity on a 1D cable as a function of kA and kI f
respectively. (B and C) PI and VP for the same parameters. (D and E) Fractional N
ular cell at 1 Hz as a function of rate constants kA and kI. (F) Fractional block o
showing that minimally proarrhythmic rate-constant combinations (low index)
constant combinations are associated with activated-state block. An area of larg
(see Figs. 3 and 6) is shown in the black boxes in A–E.kA ¼ 105 ms1mol1. There was little effect of kI variations
on CV, VP, and PI. Fig. 5, D and E, show BA and BI at
action-potential onsets a function of kA and kI. Proarrhyth-
mic regions with increased PI were associated with param-
eters that preferentially blocked the activated state (high BA
and low BI). Fig. 5 F shows values of BA and BI at action-
potential onset as a function of PI, indicating the association
with BA. CV values were little affected by the clinical drugs
(Table S1) except for high-dose flecainide (39.7 cm/s).or Naþ-channel blockers with lA and lI fixed at 10
3 ms1 and 102 ms1,
aþ-channel block for activated (BA) and inactivated (BI) states in a ventric-
f Naþ current in a ventricular cell at 1 Hz versus PI, with schematic curves
are associated with inactivated-state blockers, whereas proarrhythmic rate-
e AF-selectivity with low proarrhythmic risk and high AF-termination rates
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956 Aguilar-Shardonofsky et al.VP was similarly little affected except for high-dose flecai-
nide (41% increase).
Fig. S4 shows blocking dynamics for a cell in the 1D
cable for four representative cases. For AF-selective kA-kI
combinations, inactivated-state effects predominate and
activated-state block is negligible, whereas activated-state
block was associated with nonselective combinations.AF termination
Termination time was smallest at high kA and kI (Fig. 6 A).
Termination rates of 100% (Fig. 6 B) were achieved
with high kA, but also with relatively AF-selective regions
(AF-selectivity ratio averaging 12.81 5 0.07) with sub-
maximal kI and low kAvalues, in the region shown by a black
box in Figs. 3, 5, and 6. Parameter combinations in this
region produced little conduction slowing (Fig. 5 A) or PI
increase (Fig. 5 B). The most AF-selective area was rela-
tively inefficient, terminating only 33% of simulations.
For comparison (Table S1), lidocaine, procainamide, flecai-
nide, and ranolazine terminated 50–67%, 0%, 16–33%, and
33–100% of AFs, respectively, over the concentration range
tested. The properties of an agent with maximally AF-selec-
tive pharmacodynamics (NCB1) and an agent with submax-
imal AF selectivity but high AF-termination efficacy
(NCB2) are also shown in Table S1 for reference.
The AF-termination mechanisms were similar to those
observed in previous studies (9,19). Fig. 7 shows one
example. Generators anchored in areas of low ACh concen-
tration ([ACh]) and high action potential duration (APD;
Fig. 7 A). Annihilation events terminated the generators
but produced counter-rotating wavefronts with new genera-
tors (Fig. 7, B and C). Drug block was largest in long-APD
areas (Fig. 7 D). The ratio of depolarized cells (RAPD)
decreased along with the number of generators, leading to
termination (Fig. 7, D and E). Fig. 8 shows AF-termination
for a slightly less AF-selective but more AF-termination-
efficient blocker. The mechanisms of AF-termination are
qualitatively similar. A notable difference is the block
dynamics, with the less-effective combination in Fig. 7
showing more beat-to-beat variation in BT (peak-to-trough
variation of 0.33) than the more-effective combination in
Fig. 8 (peak-to trough variation of 0.07).Biophysical Journal 102(5) 951–960DISCUSSION
Antiarrhythmic drugs currently used for the treatment of AF
have limited efficacy and insufficient safety. The potential
benefits of sinus rhythm maintenance motivate a search
for better antiarrhythmic drugs. Here, we used mathematical
models to investigate the relationship between the pharma-
codynamic properties of Naþ-channel-blocking antiar-
rhythmic drugs and their selectivity for atrial cells at rapid
rates such as observed during AF versus ventricular cells
at sinus rhythm rates. To our knowledge, this is the first
study to systematically investigate the AF-selectivity of
Naþ-channel blockers as a function of pharmacodynamic
properties.
We found that drugs with selective binding affinity for
the inactivated state are AF-selective, although selectivity
is lost at very high inactivated-state affinities. We defined
an optimally AF-selective region associated with main-
tained conduction velocity and low PI, which is relevant
because decreased CV facilitates reentrant proarrhythmia
(20,23,24). We also defined a non-AF-selective region
(high kA) associated with decreased CV and increased PI
(Fig. 5).
The optimally AF-selective drug terminated simulated
AF in only 33% of cases (NCB1 in Table S1); however,
slightly less-AF-selective drugs had 100% AF-termination
efficacy and low proarrhythmic potential (NCB2 in Table
S1). The decrease in AF-selectivity reflects less beat-to-
beat unblocking, which was important for AF-termination
because, as Naþ-channel block slowed AF, beat-to-beat
unblocking became pronounced and prevented termination
for the most selective drugs. As tissue excitability decreases,
rotor frequency and stability decrease (8,22); hence, drugs
that retain efficacy at lower frequencies are able to destabi-
lize lower-frequency rotors more effectively compared with
drugs that are ineffective at lower frequencies.
One important finding is that AF selectivity does not
increase monotonically with increasing inactivated-state
block. Thus, drug pharmacodynamics may need to be fine-
tuned to a narrow range. A possible explanation for this
finding is that as kI increases to very high values, block accu-
mulation at lower frequencies decreases rate-selectivity and
AF-selectivity.FIGURE 6 (A) Time to termination after Naþ-
channel blocker addition on a 2D sheet of atrial
cells for the same rate-constant combinations as
in Fig. 3. (B) Percentage of successfully terminated
AF episodes. The optimally AF-selective area
terminated the arrhythmia quickly (average of
429 ms), although the percentage of successfully
terminated simulations was lower than in the
non-AF-selective region (33% vs. 100%). An
area of large AF-selectivity with low proarrhyth-
mia risk and high AF-termination rates is shown
in the black boxes (kA ¼ 101103 ms1 mol1;
kI ¼ 100 ms1 mol1).
FIGURE 7 Termination of AF after addition of maximally AF-selective Naþ-channel blocker (AF-selectivity ratio ¼ 23.9, kA ¼ 10 ms1 mol1, kI ¼
500 ms1 mol1, lA ¼ lI ¼ 102 ms1). (A) Top left: Position of generators from the time of drug application (tDRUG ¼ 1000 ms). Bottom left: Mean
APD at60 mV (APD-60) distribution. (B) Transmembrane potential snapshots of the 2D sheet at time points indicated at the upper left of each frame; black
dots denote phase singularities. (C) Number of phase singularities over time in control (black curve) and with drug (red curve). (D) Fraction of Naþ-channels
blocked at two sites (positions indicated in A); larger fractional block is in the region with longer APD. (E) Ratio of depolarized cells (RAPD) over time for
control (black curve) and with Naþ-channel blockade (red curve). (F) Transmembrane action potentials over time before and after drug addition. The time of
drug addition is shown in C–F by a vertical blue line.
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channel blockade promotes reentrant arrhythmias by
decreasing the wavelength, whereas spiral-wave theory
predicts that INa blockade is antiarrhythmic (25). Previous
work showed that a constant reduction in Naþ current termi-
nates AF by destabilizing AF-maintaining rotors (8). Com-
tois et al. (22) took this concept one step further by showing
that a rapidly unbinding Naþ-channel blocker (lidocaine)
terminates AF in a concentration-dependent manner. Here,
we expand on that work by considering the relationship
between Naþ-channel-binding properties and AF selec-
tivity/efficacy. Irrespective of AF-selectivity, we found
that termination occurred by previously described mecha-
nisms, with decreased Naþ-channel availability reducing
conduction velocity preferentially for wavefronts with
high radius of curvature, decreasing the number of genera-
tors, and increasing meandering (6,8,22,26).
To compare our optimized drugs with clinically used
Naþ-channel blockers, we repeated our analysis with re-
ported rate constants for lidocaine, procainamide, flecai-
nide, and ranolazine (Table S1). Lidocaine displayed thehighest AF-selectivity, and flecainide displayed the lowest.
Flecainide strongly decreased CVand increased VP, consis-
tent with its known proarrhythmic potential (9). Ranolazine
was the most efficacious drug and procainamide was the
least efficacious, consistent with their reported clinical
efficacies (27). In our single-cell analysis, the rate-constant
combination with the highest AF-selectivity (NCB1 in
Table S1) displayed larger AF-selectivity than the four clin-
ical drugs but limited efficacy. A combination with slightly
lower AF-selectivity (NCB2), which was twice as AF-selec-
tive as ranolazine, had 100% AF-termination efficacy.
Our findings for ranolazine are in line with the experi-
mental observations of Burashnikov et al. (27). The non-
AF-selective drug propafenone terminated vagotonic AF
faster and in 100% of experiments (27), consistent with
the faster and more efficacious AF-termination by non-
AF-selective drugs in our simulations. Our results are also
consistent with the idea that increased efficacy for AF-ter-
mination can come at the price of increasing proarrhythmic
potential: flecainide is effective for AF but has significant
proarrhythmic potential (28).Biophysical Journal 102(5) 951–960
FIGURE 8 Termination of AF after addition of a slightly less AF-selective but more effective Naþ-channel blocker (AF-selectivity ratio ¼ 12.8, kA ¼
102 ms1 mol1, kI ¼ 100 ms1 mol1, lA ¼ 10 ms1, lI ¼ 102.5 ms1). (A) Top left: Position of generators from the time of drug application (tDRUG ¼
1000 ms). Bottom left: Mean APD at 60 mV (APD-60) distribution. (B) Transmembrane potential snapshots of the 2D sheet at time points indicated at the
upper left of each frame; black dots denote phase singularities. (C) Number of phase singularities over time in control (black curve) and with drug (red curve).
(D) Fraction of Naþ-channels blocked at two sites (positions indicated in A); the larger fractional block is in the region with longer APD. (E) Ratio of depo-
larized cells (RAPD) over time for control (black curve) and with Na
þ-channel blocker (red curve). (F) Transmembrane action potentials over time before and
after drug addition. The time of drug addition is shown in C–F by a vertical blue line.
958 Aguilar-Shardonofsky et al.Ranolazine was recently shown to be an atrial-selective
open-state blocker instead of an inactivated-state blocker
(11). Ranolazine’s atrial selectivity is thought to be based
on atrial action potential characteristics, such as more nega-
tive steady-state INa inactivation voltage dependence and
gradual phase-3 repolarization, as well as the rapid dissoci-
ation kinetics and steep voltage dependence of unbinding
from the Naþ channel (11,29). Of interest, we found that
ranolazine, with more open-state blocking properties, was
more atrial-selective than rate-selective, whereas our opti-
mized inactivated-state blocker was more rate-selective
than atrial-selective. This observation points to different
mechanisms for atrial- versus rate-selectivity, which may
be interesting to pursue in the future.
Overall, rate-selectivity was the major contributor to
AF-selectivity selectivity in our pharmacodynamic analysis.
Atrial-selectivity at 1 Hz, the ability to block the Naþ
current preferentially in atria over ventricles, ranged around
unity. This finding points to a limitation of our modeling: we
assumed that the drug affinities for the Naþ channel in the
atria and ventricles were identical. However, recent workBiophysical Journal 102(5) 951–960suggests that Naþ channels may differ intrinsically between
the atria and ventricles (10). Our findings support recent
suggestions that carefully selected class I antiarrhythmic
drugs may emerge as a valid AF-selective therapeutic
strategy (27,30).
Moreno et al. (18) recently investigated the in silico
proarrhythmic potential of flecainide and lidocaine. Using
a Markov model, they reproduced the clinically observed
proarrhythmic potential for flecainide and a relatively safe
profile for lidocaine, in similarity to what we found here.
Of importance, in our study we did not assume any a priori
pharmacodynamic properties for the compound under
investigation. Instead, we analyzed Naþ-blocking drugs
for AF-termination and ventricular proarrhythmia as a
function of the pharmacodynamic parameter space. Thus,
we were able to determine the relationship between
Naþ-channel blocking properties and indices of anti-AF
efficacy/ventricular proarrhythmia. Our method has the
potential to contribute to rational approaches to define
optimized Naþ-channel blocker properties for effective
AF termination with minimized ventricular proarrhythmic
AF-Selective Sodium Channel Blockade 959potential. It is now possible, with contemporary drug-design
methods, to create candidate agents with Naþ-current block-
ing kinetics within a predicted range. This then raises the
question: What types of pharmacodynamic properties are
likely to produce the greatest likelihood of clinical efficacy
with the least likelihood of proarrhythmic adverse effects?
Our study provides an initial approach for identifying such
optimized pharmacodynamic properties.Study limitations
This study has a number of limitations. First, we principally
considered an uncharged (z ¼ 0) molecule. Use-dependent
blockers are usually charged molecules (31). Because our
goal in this study was to explore how the binding and
unbinding characteristics of Naþ-channel blockers affect
drug-selectivity, we did not analyze in detail the role of
drug charge. We did repeat the single-cell simulations for
a positively charged molecule (z¼ þ1; Fig. S2). The results
were qualitatively similar to those obtained with the
uncharged drugs, except that the introduction of charge al-
lowed for greater rate-, atrial-, and AF-selectivity. Further
consideration of the charge dependence of AF-selectivity
would be an interesting extension of this study.
Second, we considered a single inactivated state for the
Naþ channel. Previous work suggested that the Naþ channel
may have multiple inactivated states, and that transitions
between states may not be strictly sequential; for example,
a channel could transition not only from the open to the in-
activated state after activation, as assumed in our study, but
also directly from the resting to the inactivated state without
opening (closed-state inactivation) (32). Such features could
play important roles in the dynamic interaction between
class I antiarrhythmics and the Naþ channel. However, the
fundamental conclusion of our study, i.e., that inactivated-
state blockers are optimally AF-selective, would likely be
unaffected by the inclusion of multiple inactivated states.
If anything, it should be possible to achieve even greater
AF-selectivity by optimizing drugs for different inactivated
states, an idea that is worthy of further exploration.
Third, we used a square-pulse stimulus to pace the simu-
lated cells. Although this is a standard stimulus that is
widely used in modeling and experimental work, a square
pulse does not reproduce the stimulus current shape and
amplitude sensed by a cell in situ during in situ propagation,
particularly during AF, where the input current waveform
would likely be of longer duration and lower amplitude
compared with the waveform in normal sinus rhythm.
However, our findings correlate well with experimental
work, and therefore we believe that our main finding would
hold even if we used a more realistic stimulus.
Fourth, we used a 2D sheet with sinusoidal [ACh] varia-
tion and nonconducting boundaries to study AF-termination
efficacy. This choice has the limitation of introducing
geometrical biases to conclusions regarding drug efficacy(33). Indeed, the addition of Naþ-channel blocker increases
meandering, leading to rotor termination on boundaries.
Full exploration of this issue would require detailed anal-
yses in accurate 3D models and is beyond the scope of
this study. However, we did perform limited 3D simulations
in an established model (Supporting Material), which
support the main conclusions of the 2D work.
Fifth, ionic drift is an intrinsic component of mathemat-
ical action potential models that precludes true steady-state
calculations (34). We ran our simulations over a relatively
large number of cycles to minimize transient effects, and
refer to the final state as the pseudo-steady-state to make
this limitation explicit.
Sixth, we used a Hodgkin-Huxley model to simulate
drug-channel interactions. However, the choice of ionic
model can affect the dynamics of use-dependent block
(35). Wewere unable to identify a canine atrial action poten-
tial model based on a Markov formulation in the literature.
Full development of such a model is beyond the scope of
this work. Nevertheless, a limited analysis with a ventric-
ular-cardiomyocyte Markov model modified to reproduce
our atrial action potentials at 1 and 6 Hz was consistent
with our general conclusions (Supporting Material).
Seventh, we based our analysis of inactivated-state block
onlyon interactionwith the fast-inactivated state (h).However,
it is possible for drugs to interact with the slow-inactivated
state represented by j. To assess the impact of the j interaction,
we repeated our single-cell simulations with inactivated-state
block depending on combined inactivation (hj). Although
there were some small quantitative differences, our overall
findings remained unchanged (Supporting Material).
Finally, the pathophysiological significance of our
measure of ventricular proarrhythmia, the PI, is controver-
sial. We chose the PI because it was previously used to study
proarrhythmic drug determinants (21), and it is relatively
simple to define and analyze. However, the PI in a cable
of normal ventricular cardiomyocytes does not reproduce
potentially important components of arrhythmogenic envi-
ronments in vivo, such as tissue heterogeneity and diseased
myocardium, and might therefore underestimate the proar-
rhythmic potential in our study. It would be interesting in
future work to explore the relationship between Naþ-
channel blocking pharmacodynamics and more complex
and clinically relevant proarrhythmia indices (e.g.,
arrhythmia promotion) in geometrically and physiologically
realistic simulations (e.g., ischemic conditions).CONCLUSIONS
The development of efficacious and safe antiarrhythmic
agents for the prevention and treatment of AF is an impor-
tant unmet need in clinical medicine. Using realistic math-
ematical models of atrial and ventricular cardiomyocytes,
we found that Naþ-channel blockers targeting the inacti-
vated state are more AF-selective and less proarrhythmicBiophysical Journal 102(5) 951–960
960 Aguilar-Shardonofsky et al.than those targeting the activated state. Our findings may
contribute to the effort to optimize class I antiarrhythmic
drug state-dependent interactions with Naþ channels and
develop selective, safer, and effective anti-AF agents.SUPPORTING MATERIAL
Simulations, references, two tables, and 10 figures are available at http://
www.biophysj.org/biophysj/supplemental/S0006-3495(12)00114-2.
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